ONCOGENEX PHARMACEUTICALS IN's ticker is OGXI and the CUSIP is 68230A106. A total of 27 filers reported holding ONCOGENEX PHARMACEUTICALS IN in Q2 2017. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2017 | $53,000 | -20.9% | 148,356 | -2.8% | 0.00% | – |
| Q1 2017 | $67,000 | -10.7% | 152,559 | +0.4% | 0.00% | – |
| Q4 2016 | $75,000 | -1.3% | 151,989 | +0.3% | 0.00% | – |
| Q3 2016 | $76,000 | -49.7% | 151,609 | +0.1% | 0.00% | – |
| Q2 2016 | $151,000 | +96.1% | 151,514 | +33.6% | 0.00% | – |
| Q1 2016 | $77,000 | -43.8% | 113,419 | -0.1% | 0.00% | – |
| Q4 2015 | $137,000 | -45.6% | 113,514 | +0.2% | 0.00% | – |
| Q3 2015 | $252,000 | +6.8% | 113,324 | +11.6% | 0.00% | – |
| Q2 2015 | $236,000 | +69.8% | 101,522 | +56.9% | 0.00% | – |
| Q1 2015 | $139,000 | -6.1% | 64,698 | +0.1% | 0.00% | – |
| Q4 2014 | $148,000 | -14.0% | 64,641 | +0.1% | 0.00% | – |
| Q3 2014 | $172,000 | -29.2% | 64,584 | -1.1% | 0.00% | – |
| Q2 2014 | $243,000 | -72.0% | 65,332 | -11.6% | 0.00% | -100.0% |
| Q1 2014 | $868,000 | +101.4% | 73,870 | +42.8% | 0.00% | – |
| Q4 2013 | $431,000 | -13.6% | 51,738 | -3.9% | 0.00% | – |
| Q3 2013 | $499,000 | -1.0% | 53,840 | +4.7% | 0.00% | – |
| Q2 2013 | $504,000 | – | 51,412 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Abingworth LLP | 396,104 | $400,000 | 0.42% |
| Ancora Advisors LLC | 50,865 | $51,000 | 0.01% |
| EAGLE GLOBAL ADVISORS LLC | 145,710 | $146,000 | 0.00% |
| Acrospire Investment Management LLC | 5,200 | $5,000 | 0.00% |
| A.R.T. Advisors, LLC | 57,954 | $57,000 | 0.00% |
| Renaissance Technologies | 876,100 | $876,000 | 0.00% |
| PRELUDE CAPITAL MANAGEMENT, LLC | 4,600 | $5,000 | 0.00% |
| Cutler Group LLC / CA | 11,048 | $11,000 | 0.00% |
| PANAGORA ASSET MANAGEMENT INC | 133,846 | $134,000 | 0.00% |
| PRICE T ROWE ASSOCIATES INC /MD/ | 46,100 | $46,000 | 0.00% |